Medicure (Medicure) Debt-to-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Medicure Debt-to-Asset?

Medicure's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.20 Mil. Medicure's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.16 Mil. Medicure's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $21.18 Mil. Medicure's debt to asset for the quarter that ended in Mar. 2024 was 0.02.

Medicure Debt-to-Asset Historical Data

The historical data trend for Medicure's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicure Debt-to-Asset Chart

Medicure Annual Data

Trend

May14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.04

0.03

0.02

Medicure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.03	0.02	0.02	0.02

Competitive Comparison of Medicure's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicure's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicure's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Medicure's Debt-to-Asset falls into.

Medicure Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Medicure's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.235	+	0.171)	/	20.915
	=	0.02

Medicure's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.197	+	0.155)	/	21.183
	=	0.02

Medicure (OTCPK:MCUJF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Medicure Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Medicure's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicure (Medicure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicure Inc (OTCPK:MCUJF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NGQ1:Germany MPH:Canada

Address

2 - 1250 Waverley Street, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.medicure.com

Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.